[Effects of danazol therapy in endometriosis on the blood picture and blood coagulation].

Abstract

Over a six-month period, 62 endometriosis patients were given 600 mg per day of the ethisterone derivative danazol. Blood count and coagulation status were checked before and during treatment. There was a significant increase (p less than 0.05) in hemoglobin and hematocrit. There were no changes in RBC, leukocyte count, or thrombocyte count; the mean cellular erythrocyte volume, thrombin time, thromboplastin time, and partial thromboplastin time also remained unchanged, as did factors VII, VIII, X, XII, and alpha-1-antitrypsin. Antithrombin III levels increased, while alpha-2-macroglobulin values decreased. Only the drop in fibrinogen, to pathologic values, and the increase in plasminogen reached significant levels (p less than 0.01). These in part contradictory changes suggest that hypocoagulability occurs under danazol medication; however, its clinical relevance is unclear.

• Authors: K W Schweppe, C Ebert, U Cirkel
• Journal: Geburtshilfe und Frauenheilkunde (Geburtshilfe Frauenheilkd) Vol. 48 Issue 9 Pg. 634-6 (Sep 1988) ISSN: 0016-5751 [Print] Germany
• Vernacular Title: Auswirkungen der Danazol-Therapie bei Endometriose auf Blutbild und Gerinnung.
• PMID: 3181711 (Publication Type: English Abstract, Journal Article)

Chemical References

• Blood Coagulation Factors
• Pregnadienes
• Danazol

Topics

• Adult
• Blood Cell Count (drug effects)
• Blood Coagulation Disorders (chemically induced)
• Blood Coagulation Factors (metabolism)
• Danazol (adverse effects, therapeutic use)
• Endometriosis (blood, drug therapy)
• Female
• Genital Neoplasms, Female (blood, drug therapy)
• Hematocrit
• Hemoglobinometry
• Humans
• Pregnadienes (adverse effects)